Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
modzatinib
- Development stage
- Unknown
- Lead developer
- Aclaris Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Modzatinib (ATI-2138) is an orally bioavailable small molecule kinase inhibitor developed by Aclaris Therapeutics. It is designed to covalently inhibit Janus kinase 3 (JAK3) and interleukin-2-inducible T-cell kinase (ITK). By targeting these two kinases, modzatinib aims to modulate both the JAK-STAT signaling pathway and T-cell receptor signaling, which are central to the pathogenesis of various inflammatory and autoimmune diseases. It is currently being evaluated in Phase 2 clinical trials for the treatment of moderate-to-severe atopic dermatitis and various forms of lichen planus, including oral, cutaneous, and lichen planopilaris.
- Other names
- ATI-2138ATI2138ATI 2138
02
Targets
Beyond the preview
Go deeper on modzatinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on modzatinib.